INDSWFTLAB.NS

Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.